Abstract:Background: Cryptococcus neoformans infections occur in immunocompromised patients, especially those with HIV infection, chemoradiotherapy after cancer, and organ transplantation. Infection can cause pneumonia and meningoencephalitis in severe cases with a high mortality rate if not treated. Although fluconazole and amphotericin B are the first-line treatments for cryptococcosis, the rate of fluconazole resistance has increased significantly due to long-term use. Minocycline is a derivative of tetracycline that exerts its antibacterial effect through inhibition of bacterial protein synthesis. It is also able to pass the blood-brain barrier to act on the central nervous system. The present study investigates the effects of minocycline in combination with antifungals in treating C. neoformans. Objective: To determine in vitro interactions of minocycline combined with itraconazole, voriconazole, posaconazole, fluconazole and amphotericin B against C. neoformans. Methods: The minimum inhibitory concentrations (MIC) of the antifungals were determined by the CLSI Clinical and Laboratory Standards Institute M27-A3 microdilution method. The in vitro synergistic effects of minocycline combined with itraconazole, voriconazole, posaconazole, fluconazole, and amphotericin B on C. neoformans were detected by the broth microdilution checkerboard technique and disk diffusion testing. Results and conclusion: The working concentration ranges were 0.125-4 µg/mL for itraconazole, 0.03-0.125 µg/ml for voriconazole, 0.03-1 µg/ml for posaconazole, 0.25-16 µg/ml for fluconazole, and 0.125-2 µg/ml for amphotericin B. The synergistic rates of minocycline combinations against C. neoformans were 55% with itraconazole, 10% with voriconazole, 85% with posaconazole, 20% with fluconazole, and 70% with amphotericin B. The effective MIC value of minocycline in the synergistic combination decreased to 2-32 µg/ml, while the MIC of itraconazole decreased to 0.03-0.125 µg/ml, voriconazole 0.03-0.125 µg/ml, posaconazole 0.03-0.125 µg/ml, 0.125-4 µg/ml fluconazole, and 0.06-0.50 µg/ml amphotericin B. The disk diffusion assay showed that the plates containing minocycline and antifungal drugs produced inhibition zones with diameters larger than the single drug plates. Minocycline showed no antagonistic effect in the combinations. In conclusion, the combination of minocycline and azoles or amphotericin B has synergistic effects against C. neoformans in vitro.

Antifungal activity of combination of caspofungin and voriconazole, itraconazole or amphotericin B against clinical strains of Scedosporium apiospermum in vitro

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

In Vitro Interaction of Itraconazole with Amphotericin B, Caspofungin, and Terbinafine Against Clinical Isolates of Trichosporon asahii

In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales

In vitro interactions of itraconazole with caspofungin or terbinafine against Sporothrix globosa

In Vitro Combined Activity of Amphotericin B, Caspofungin and Voriconazole Against Clinical Isolates of Trichosporon Asahii

In Vitro Synergistic Antifungal Activities of Caspofungin in Combination with Fluconazole or Voriconazole Against Candida Species Determined by the Etest Method

In vitro activities of six antifungal agents and their combinations against Chaetomium spp.

Antifungal Activity of Antifungal Drugs, as Well as Drug Combinations Against Exophiala dermatitidis

In Vitro Triple Combination of Antifungal Drugs against Clinical Scopulariopsis and Microascus Species

In vitro susceptibility testing of the combination of terbinafine and itraconazole against dematiaceous fungi

Combination of itraconazole and terbinafine in treating sporotrichosis and their in vitro antifungal activities against Sporothrix schenckii

In Vitro Susceptibility Testing of Aspergillus Spp. Against Voriconazole, Itraconazole, Posaconazole, Amphotericin B and Caspofungin

Drug combinations against Mucor irregularis in vitro.

In Vitro and in Vivo Efficacy of a Synergistic Combination of Itraconazole and Verapamil Against Aspergillus Fumigatus

In Vitro Interaction of Terbinafine with Itraconazole and Amphotericin B Against Fungi Causing Chromoblastomycosis in China.

Synergism of Caspofungin and Terbinafine Against Clinical and Environmental Isolates of Cryptococcus Neoformans

In Vitro Activities of Nine Antifungal Drugs and Their Combinations against Phialophora verrucosa

Susceptibility Testing of the Combination of Itraconazole and Terbinafine in Vitro

In Vitro Interaction Between Azoles and Cyclosporin A Against Clinical Isolates of Candida Albicans Determined by the Chequerboard Method and Time-Kill Curves

In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans